Hyperosmotic/hyperoncotic solutions for resuscitation of hypodynamic shock

• US 4,908,350 A
• Filed: 02/24/1988
• Issued: 03/13/1990
• Est. Priority Date: 10/31/1985
• Status: Expired due to Term

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Holcroft, James W., Kramer, George C.
• Primary Examiner(s): Stone, Jacqueline M.
• Application Number:
  US07/163,137
• Time in Patent Office: 748 Days
• Field of Search: 514/2, 514/59, 514/921, 514/60, 514/23, 424/101, 424/153, 424/680
• US Class Current: 514/13.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients

Abstract

A physiologically acceptable solution which is both hyperosmotic and hyperoncotic with respect to blood plasma and has utility in treating patients experiencing or threatening to experience hypodynamic shock. The physiologically acceptable solution comprises a hyperosmotic concentration of a crystalloid (in excess of about 1800 mOsms) and hyperoncotic concentration of a colloid (in excess of about 30 mm Hg). The physiologically acceptable solution is easily administered by single, rapid infusion of approximately 4 to 5 ml/kg of body weight and results in a rapid and sustained normalization of circulatory function.

Claims

1. A physiologically acceptable solution for treating hypodynamic circulatory shock in a mammal, said solution containing a crystalloid having a molecular weight less than about 1000 in a concentration of at least about 1800 mOsms and a colloid having a molecular weight in excess of 30,000 in a concentration so as to render said solution hyperoncotic relative to the colloidal osmotic pressure of the normal blood plasma of said mammal.

2. The physiologically acceptable solution of claim 1, wherein the crystalloid is selected from the group consisting of physiologically acceptable sodium salts, sugar alcohols, and sugars.

3. The physiologically acceptable solution of claim 1, wherein said crystalloid concentration is in excess of about 1800 mOsms.

4. The physiologically acceptable solution of claim 1, wherein said crystalloid concentration is about 2400 mOsms.

5. The physiologically acceptable solution of claim 1, wherein said colloid is selected from the group consisting of physiologically acceptable dextran, hydroxyethyl starch, or protein.

6. The physiologically acceptable solution of claim 1, wherein said hyperoncotic concentration is at least about 70 mm Hg.

18. The physiologically acceptable solution of claim 1, wherein said hyperoncotic pressure is at least about 20 mm Hg.

19. The physiologically acceptable solution of claim 1 wherein said colloid is gelatin.

7. A physiologically acceptable solution comprising saline and dextran, having an osmolarity of about 2400 mOsms and an oncocity of about 70 mm Hg.

8. A method of preventing or treating hypodynamic circulatory shock in a mammal, comprising the step of administering to said mammal in a condition of existing or impending shock, a therapeutically effective dose of a physiologically acceptable solution, said solution containing a crystalloid having a molecular weight less than about 1000 in a concentration of at least about 1800 mOsms and a colloid having a molecular weight in excess of 30,000 in a concentration so as to render said solution hyperoncotic relative to the colloidal osmotic pressure of the normal blood plasma of said mammal.

9. The method of claim 8, wherein said crystalloid is selected from the group consisting of physiologically acceptable sodium salts, sugar alcohols, and sugars.

10. The method of claim 8, wherein said crystalloid concentration is in excess of about 1800 mOsms.

11. The method of claim 8, wherein said crystalloid concentration is about 2400 mOsms.

12. The method of claim 8, wherein said colloid is selected from the group consisting of physiologically acceptable dextran, hydroxyethyl starch, and protein.

13. The method of claim 8, wherein said hyperoncotic concentration is in excess of about 30 mm Hg.

14. The method of claim 8, wherein said hyperoncotic concentration is at least about 70 mm Hg.

15. The method of claim 8, wherein said physiologically acceptable solution is infused intravascularly.

16. The method of claim 8, wherein said physiologically acceptable solution is injected.

17. The method of claim 8, wherein said therapeutically effective dose is about 4 to 5 ml/kg of body weight.

20. The method of claim 8 wherein said colloid is gelatin.